TY - JOUR
T1 - Barriers in nanomedicine
T2 - The importance of defined chemistry and engineering approaches for clinical translation
AU - Chang, Huei Huei
AU - Braswell, Shaneen
AU - George, Jonathan
AU - Gryka, Mark
AU - Kim, Sumin
AU - Kolmodin, Nicolas
AU - Kumar, Manu
AU - Seadler, Benjamin
AU - Sonoiki, Oluwayemisi
AU - Pan, Dipanjan
N1 - Publisher Copyright:
© Springer International Publishing Switzerland 2014.
PY - 2016/6/1
Y1 - 2016/6/1
N2 - The multidisciplinary research of nanomedicine unites the unique prospective of nanotechnology with biology and medicine. A myriad of technological advancements has been made over the past two decades demonstrating the high impending growth of this field for clinical translation. In tandem, the advancements in chemistry, molecular biology, and engineering have molded this field emphasizing the early detection and treatment of diseases at the molecular and cellular level. Myriads of nanomedicine platforms have been proposed and developed and tested in laboratories and in preclinical models. However, very few have been translated to clinical trials. It is, therefore, a critical issue to recognize the factors affecting their eventual application in human. Towards this aim, we critically review our present understanding of the biological and biophysical obstacles encountered by the nanoagents, which we hope will promote the development of nanotechnologies in terms of future translational and clinical applications.
AB - The multidisciplinary research of nanomedicine unites the unique prospective of nanotechnology with biology and medicine. A myriad of technological advancements has been made over the past two decades demonstrating the high impending growth of this field for clinical translation. In tandem, the advancements in chemistry, molecular biology, and engineering have molded this field emphasizing the early detection and treatment of diseases at the molecular and cellular level. Myriads of nanomedicine platforms have been proposed and developed and tested in laboratories and in preclinical models. However, very few have been translated to clinical trials. It is, therefore, a critical issue to recognize the factors affecting their eventual application in human. Towards this aim, we critically review our present understanding of the biological and biophysical obstacles encountered by the nanoagents, which we hope will promote the development of nanotechnologies in terms of future translational and clinical applications.
UR - http://www.scopus.com/inward/record.url?scp=84975796818&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84975796818&partnerID=8YFLogxK
U2 - 10.1007/7355_2014_68
DO - 10.1007/7355_2014_68
M3 - Article
AN - SCOPUS:84975796818
SN - 1862-2461
VL - 20
SP - 1
EP - 28
JO - Topics in Medicinal Chemistry
JF - Topics in Medicinal Chemistry
ER -